Results 181 to 190 of about 3,235 (226)

An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma

Expert Opinion on Drug Discovery, 2023
Tezepelumab is a human IgG2 monoclonal antibody (mAb) that binds to human thymic stromal lymphopoietin (TSLP), preventing its interaction with the receptor and inhibiting multiple downstream inflammatory pathways. TSLP is an alarmin relevant to the pathogenesis of asthma.This article focuses on the significance of TSLP in developing asthma and how ...
Paola Rogliani, Josuél Ora, Maria Gabriella Matera   +2 more
exaly   +4 more sources

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

Expert Opinion on Investigational Drugs, 2019
Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma.
Giuseppe Spadaro, Mariantonia Braile, Remo Poto   +2 more
exaly   +2 more sources

Effectiveness and Safety of Tezepelumab in a Diverse Population of US Patients with Severe Asthma: Initial Results of the PASSAGE Study

Advances in Therapy
Clinical trials for severe uncontrolled asthma (SUA) often underrepresent or exclude key patient populations. The phase 4 PASSAGE study assesses the effectiveness and safety of tezepelumab in a diverse, real-world US population of patients with SUA ...
N. Lugogo, P. Akuthota, K. Sumino, S. K. Mathur, A. Burnette, Andrew W. Lindsley, J. Llanos, C. Marchese, C. S. Ambrose, Benjamin Emmanuel   +9 more
semanticscholar   +1 more source

The effectiveness and value of tezepelumab for severe asthma

Journal of Managed Care & Specialty Pharmacy, 2022
DISCLOSURES: Drs Rind, Campbell, Pearson, Ms Herce-Hagiwara, Ms Fluetsch, and Ms Herron-Smith report grants from Arnold Ventures; Kaiser Foundation Health Plan, Inc; The Patrick and Catherine Donaghue Medical Research Foundation; Blue Cross Blue Shield of Massachusetts; and California Healthcare Foundation during the course of this study.
David M, Rind, R Brett, McQueen, Serina, Herron-Smith, Belén, Herce-Hagiwara, Eric, Gutierrez, Jon D, Campbell, Noemi, Fluetsch, Steven D, Pearson   +7 more
openaire   +2 more sources

Tezepelumab inhibits highly functional truncated thymic stromal lymphopoietin in chronic rhinosinusitis

Journal of Allergy and Clinical Immunology
Background: Thymic stromal lymphopoietin (TSLP) and its functional cleavage products are elevated in nasal polyps (NPs) and play important roles in type 2 (T2) inflammation in chronic rhinosinusitis (CRS) with NPs (CRSwNP) by activating myeloid dendritic
Aiko Oka, Aiko I. Klingler, Masanori Kidoguchi, J. Poposki, L. Suh, Junqin Bai, Whitney W. Stevens, Anju T. Peters, L. Grammer, K. Welch, Stephanie S Smith, D. Conley, R. Schleimer, Robert C. Kern, Bruce K. Tan, S. Fujieda, Mitsuhiro Okano, Atsushi Kato   +17 more
semanticscholar   +1 more source

Switching to tezepelumab from other biologics in patients with severe asthma: a retrospective study.

Respiratory Investigation
BACKGROUND Tezepelumab, an anti-thymic stromal lymphopoietin antibody, has shown efficacy in reducing exacerbations and improving control in patients with severe asthma (SA), including those with low type 2 (T2) inflammation.
Toshiyuki Sumi, Taiki Ishigooka, Keigo Matsuura, Takumi Ikeda, Yuta Koshino, Keito Suzuki, Yuichi Yamada, Hirofumi Chiba   +7 more
semanticscholar   +1 more source

Tezepelumab as add‐on treatment for severe asthma

Prescriber, 2023
Tezepelumab (Tezspire) is a new monoclonal antibody therapy for add‐on treatment in adolescents and adults with inadequately controlled severe asthma. This article outlines its mode of action, indication and clinical trial outcomes.
openaire   +1 more source

Evaluating the efficacy and safety of tezepelumab in the treatment of chronic rhinosinusitis with nasal polyps.

Immunotherapy
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating inflammatory disease associated with high recurrence rates and limited response to current therapies.
J. Priessnitz, Jaekeun Jung, Joseph K. Han, Kent Lam   +3 more
semanticscholar   +1 more source

The impact of tezepelumab therapy on perceived asthma triggers: a multicenter real-life study

Journal of Asthma
Objective Asthma exacerbations are often triggered by factors such as respiratory infections, allergens, exercise, and airway irritants, significantly affecting patients’ respiratory symptoms and quality of life.
Andrea Portacci, G. Scioscia, S. Dragonieri, M. Aliani, E. Lulaj, Francesca Montagnolo, Pietro Magaletti, Piera Soccio, Luciana Salerno, D. Lacedonia, G. E. Carpagnano   +10 more
semanticscholar   +1 more source

A Pharmacovigilance Analysis of Post-Marketing Safety of Tezepelumab

Journal of Allergy and Clinical Immunology: in Practice
Tezepelumab has shown promising efficacy for adult patients with severe asthma since its approval. However, the post-marketing safety evaluation of tezepelumab is currently lacking.To investigate the post-marketing safety of tezepelumab based on the US Food and Drug Administration Adverse Event Reporting System database.Adverse events (AEs) reported ...
Huqun, Li, Chongshu, Wang, Cuilian, Guo
exaly   +3 more sources